27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- As Sanofi SA (NASDAQ:SNY) schedules to report Q4 FY22 earnings early next month, it expects a positive currency impact in Q4 2022.
- The company expects growth driven by Dupixent, while Neurology & Immunology be slightly down. It also expects record flu season sales.
- Sanofi said its preliminary estimate of currency movements be approximately +4.5% and +5.5% on Q4 sales and a positive impact of +6% and +7% on its Q4 business EPS.
- Sanofi expects a positive impact of +6.5% and +7.5% for FY22 sales and +8% and +9% for EPS. Previously, Sanofi forecasted a currency impact of +9.5% and +10.5% on FY22 EPS.
- The company also said that an arbitration award concerning the U.S. litigation about the heartburn drug Zantac was expected to be rendered sometime in 2023 and at the end of the first quarter at the earliest.
- Sanofi "remains confident in its legal defenses" regarding the litigation.
- In December, the federal Multi-District Litigation court determined insufficient evidence that ranitidine can cause plaintiffs' alleged cancers.
- This ruling significantly decreased the litigation scope and substantiated Sanofi's scientific defenses to the claims being asserted. In mid-December, Sanofi reached a favorable agreement to resolve Mr. Goetz's claims against it (California court case). With this settlement, Sanofi is not a defendant in any of the other California cases set for trial in 2023
- Price Action: SNY shares are down 1.16% at $48.43 during the premarket session on the last check Wednesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!